Bio-Rad Laboratories, Inc. Class B
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO.B and other ETFs, options, and stocks.About BIO.B
Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics.
BIO.B Key Statistics
Stock Snapshot
As of today, Bio-Rad Laboratories, Inc. Class B(BIO.B) shares are valued at $294.17. The company's market cap stands at 7.16B, with a P/E ratio of 49.00.
On 2026-05-23, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock traded between a low of $294.17 and a high of $294.17. Shares are currently priced at $294.17, which is 0.0% above the low and 0.0% below the high.
The Bio-Rad Laboratories, Inc. Class B(BIO.B)'s current trading volume is 1, compared to an average daily volume of 413.85.
During the past year, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock moved between $244.54 at its lowest and $321.12 at its peak.
During the past year, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock moved between $244.54 at its lowest and $321.12 at its peak.
BIO.B News
If you are wondering whether Bio-Rad Laboratories at around US$287.74 is priced attractively or not, it helps to step back and look at what the recent share per...
Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (NYSE:BIO). The activist position signals potential pressure for changes in...
Advertisement Recent performance snapshot Bio-Rad Laboratories (BIO) has drawn investor attention after a mixed run. The stock is up 13.9% over the past day a...
Analyst ratings
50%
of 6 ratingsMore BIO.B News
Bio-Rad develops instruments and software used by hospitals, blood banks, and medical laboratories. However, the company's founding family retains majority voti...
Bio-Rad (BIO) is up 11.6%, or $28.75 to $276.28. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-perform...
Activist investor Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories (BIO). According to the Wall Street Journal, Elliot...
Earlier this week, RBC Capital resumed coverage of Bio-Rad Laboratories, assigning an Outperform rating and emphasizing expectations for improved margins under...
Bio-Rad’s stock has dropped over 70% since trading at peak levels of over $800 a share in late 2021, during the Covid-19 pandemic. denis charlet / AFP / Getty I...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.